News / Health

    GSK Cancer Vaccine Fails Again, Testing Continues

    FILE - The logo of GlaxoSmithKline (GSK) is seen on its office building in Shanghai.
    FILE - The logo of GlaxoSmithKline (GSK) is seen on its office building in Shanghai.
    Reuters
    An experimental cancer vaccine from GlaxoSmithKline has failed in a second test - this time against lung cancer - but the British company said it still hoped to identify a sub-group of patients on which it would work.
     
    Thursday's news that the MAGE-A3 therapeutic vaccine did not help patients with non-small cell lung cancer in a late-stage study is a further blow to the high-risk, high-reward project after a similar setback in melanoma in September.
     
    Unlike traditional preventative vaccines, the MAGE-A3 treatment is designed for people with established disease, helping their immune systems to prevent the return of disease after surgery.
     
    The large Phase III study, involving more than 2,000 lung cancer patients, found that the experimental therapy did not help patients live longer without their disease recurring.
     
    Nonetheless, GSK plans to continue the clinical trial in the hope of finding a sub-population that will benefit. It is also doing the same with patients suffering from melanoma and results of analyzes looking at these sub-sets of patients with particular genetic profiles are expected in 2015.
     
    Vincent Brichard, head of immunotherapeutics at GSK Vaccines, said the company was disappointed by the outcome but remained committed to the project.
     
    Shares in GSK fell by 2 percent by 0945 GMT, underperforming a 0.7 percent decline in the European drugs sector.
     
    Many investors had been expecting a disappointing read-out from the lung cancer study, following the earlier setback in melanoma, and there are doubts as to whether GSK will be able to prove the vaccine works for a smaller group of genetically selected patients.
     
    But despite the problems GSK Chief Executive Andrew Witty painted a surprisingly upbeat picture of prospects for MAGE-A3 at full-year results last month. Witty described the cancer vaccine and another drug for heart disease called darapladib that has also disappointed in tests as among the most promising in the company's pipeline.
     
    10 percent chance
     
    Citi analyst Andrew Baum said he estimated there was a 10 percent probability that MAGE-A3 could result in a significant benefit in a gene-signature defined population group, which would still be a substantial market.
     
    As a result, Citi has a risk-adjusted sales forecast for the product of 216 million pounds ($360 million) in 2022.
     
    Other companies, including Bristol-Myers Squibb, Roche and Merck & Co, have had some recent notable successes in clinical trials of innovative drugs to boost the immune system, but GSK is still pushing the scientific boundaries with its vaccine-based approach.
     
    So-called immunotherapy, in which the body's own immune system is enlisted to fight tumor cells, is a hot area of pharmaceutical research and development at the moment, although cancer vaccines have proved difficult to develop over the years.
     
    U.S.-based Agenus has contributed technology to the GSK vaccine and its shares are sensitive to news on the project. The vaccine contains Agenus' QS-21 Stimulon adjuvant, or booster.
     
    Although news on MAGE-A3 and darapladib has been disappointing for GSK, the company's overall drug research has been improving recently, with notable new drug approvals in 2013 for HIV, cancer and respiratory disease.
     
    GSK, which is the only major drugmaker to report its internal rate of return on R&D investment, said last month that returns had now reached 13 percent, up from 12 percent two years earlier and 11 percent in 2010. It has set a target of reaching 14 percent.

    You May Like

    Syrian Torture Victim Recounts Horrors

    'You make them think you have surrendered' says Jalal Nofal, a doctor who was jailed and survived repeated interrogations in Syria

    Mandela’s Millions Paid to Heirs, But Who Gets His Country Home?

    Saga around $3 million estate of country's first democratic president is far from over as Winnie Mandela’s fight for home overshadows payouts

    Guess Which Beach is 'Best in the US'?

    Hawaii’s Hanauma Bay tops an annual "top 10" list compiled by a coastal scientist, also known as Doctor Beach

    Featured Videos

    Your JavaScript is turned off or you have an old version of Adobe's Flash Player. Get the latest Flash player.
    Chinese-Americans Heart Trump, Bucking National Trendi
    X
    May 27, 2016 5:57 AM
    A new study conducted by three Asian-American organizations shows there are three times as many Democrats as there are Republicans among Asian-American voters, and they favor Hillary Clinton over Donald Trump. But one group, called Chinese-Americans For Trump, is going against the tide and strongly supports the business tycoon. VOA’s Elizabeth Lee caught up with them at a Trump rally and reports from Anaheim, California.
    Video

    Video Chinese-Americans Heart Trump, Bucking National Trend

    A new study conducted by three Asian-American organizations shows there are three times as many Democrats as there are Republicans among Asian-American voters, and they favor Hillary Clinton over Donald Trump. But one group, called Chinese-Americans For Trump, is going against the tide and strongly supports the business tycoon. VOA’s Elizabeth Lee caught up with them at a Trump rally and reports from Anaheim, California.
    Video

    Video Reactions to Trump's Success Polarized Abroad

    What seemed impossible less than a year ago is now almost a certainty. New York real estate mogul Donald Trump has won the number of delegates needed to secure the Republican presidential nomination. The prospect has sparked as much controversy abroad as it has in the United States. Zlatica Hoke has more.
    Video

    Video Drawings by Children in Hiroshima Show Hope and Peace

    On Friday, President Barack Obama will visit Hiroshima, Japan, the first American president to do so while in office. In August 1945, the United States dropped an atomic bomb on the city to force Japan's surrender in World War II. Although their city lay in ruins, some Hiroshima schoolchildren drew pictures of hope and peace. The former students and their drawings are now part of a documentary called “Pictures from a Hiroshima Schoolyard.” VOA's Deborah Block has the story.
    Video

    Video Vietnamese Rapper Performs for Obama

    A prominent young Vietnamese artist told President Obama said she faced roadblocks as a woman rapper, and asked the president about government support for the arts. He asked her to rap, and he even offered to provide a base beat for her. Watch what happened.
    Video

    Video Roots Run Deep for Tunisia's Dwindling Jewish Community

    This week, hundreds of Jewish pilgrims are defying terrorist threats to celebrate an ancient religious festival on the Tunisian island of Djerba. The festivities cast a spotlight on North Africa's once-vibrant Jewish population that has all but died out in recent decades. Despite rising threats of militant Islam and the country's battered economy, one of the Arab world's last Jewish communities is staying put and nurturing a new generation. VOA’s Lisa Bryant reports.
    Video

    Video Meet Your New Co-Worker: The Robot

    Increasing numbers of robots are joining the workforce, as companies scale back and more processes become automated. The latest robots are flexible and collaborative, built to work alongside humans as opposed to replacing them. VOA’s Tina Trinh looks at the next generation of automated employees helping out their human colleagues.
    Video

    Video Wheelchair Technology in Tune With Times

    Technologies for the disabled, including wheelchair technology, are advancing just as quickly as everything else in the digital age. Two new advances in wheelchairs offer improved control and a more comfortable fit. VOA's George Putic reports.
    Video

    Video Baby Boxes Offer Safe Haven for Unwanted Children

    No one knows exactly how many babies are abandoned worldwide each year. The statistic is a difficult one to determine because it is illegal in most places. Therefore unwanted babies are often hidden and left to die. But as Erika Celeste reports from Woodburn, Indiana, a new program hopes to make surrendering infants safer for everyone.
    Video

    Video California Celebration Showcases Local Wines, Balloons

    Communities in the U.S. often hold festivals to show what makes them special. In California, for example, farmers near Fresno celebrate their figs and those around Gilmore showcase their garlic. Mike O'Sullivan reports that the wine-producing region of Temecula offers local vintages in an annual festival where rides on hot-air balloons add to the excitement.
    Video

    Video US Elementary School Offers Living Science Lessons

    Zero is not a good score on a test at school. But Discovery Elementary is proud of its “net zero” rating. Net zero describes a building in which the amount of energy provided by on-site renewable sources equals the amount of energy the building uses. As Faiza Elmasry tells us, the innovative features in the building turn the school into a teaching tool, where kids can't help but learn about science and sustainability. Faith Lapidus narrates.

    Special Report

    Adrift The Invisible African Diaspora